A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
- Conditions
- CholangiocarcinomaUrothelial CarcinomaCervical CancerSquamous Cell Carcinoma of Head and Neck
- First Posted Date
- 2015-06-24
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 73
- Registration Number
- NCT02479178
- Locations
- ๐ท๐บ
Investigative Site: #79, Saint Petersburg, Russian Federation
๐ท๐บInvestigative Site: #70, Moscow, Russian Federation
๐ท๐บInvestigative Site: #75, Kazan, Russian Federation
A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer
- Conditions
- KRAS Positive Patients With Non-small Cell Lung CancerSquamous Cell Non-small Cell Lung Cancer
- Interventions
- Drug: BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 69
- Registration Number
- NCT02283320
- Locations
- ๐ท๐บ
Investigative Site: #70, Moscow, Russian Federation
๐บ๐ธInvestigative Site: #39, Amarillo, Texas, United States
๐บ๐ธInvestigative Site: #37, Yakima, Washington, United States
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2013-03-18
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 42
- Registration Number
- NCT01812746
- Locations
- ๐บ๐ธ
Investigational Site #11, New York, New York, United States
๐บ๐ธInvestigational Site #12, Ann Arbor, Michigan, United States
๐บ๐ธInvestigative Site #17, Fort Meyers, Florida, United States
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2016-04-15
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 64
- Registration Number
- NCT01792479
- Locations
- ๐บ๐ธ
Investigative Site #08, Newnan, Georgia, United States
๐ท๐บSite #17, Krasnodar, Russian Federation
๐บ๐ธInvestigative Site #10, Goodyear, Arizona, United States
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
- Conditions
- Solid TumorsMetastatic CancerCancer
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2016-02-09
- Lead Sponsor
- BIND Therapeutics
- Target Recruit Count
- 58
- Registration Number
- NCT01300533
- Locations
- ๐บ๐ธ
Investigational Site #06, Fort Meyers, Florida, United States
๐บ๐ธInvestigational Site #02, Greenbrae, California, United States
๐บ๐ธInvestigational Site #04, Los Angeles, California, United States